Hypertension — a sustained elevation of arterial blood pressure above 130/80 mmHg — affects an estimated 1.28 billion adults worldwide, making it the single most common modifiable risk factor for cardiovascular disease, stroke, and premature death. [1] Yet despite the availability of effective and inexpensive medications, fewer than one in four people with hypertension achieve adequate blood pressure control. The disease progresses silently for years, damaging the endothelium, stiffening the arteries, and straining the heart before any symptom appears.

The gap is not just about adherence. Current antihypertensive drugs — ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, and beta-blockers — lower blood pressure primarily through hemodynamic mechanisms: reducing vascular tone, lowering cardiac output, or decreasing sodium and fluid retention. They do not address the underlying vascular pathology that sustains the hypertensive state. When treatment stops, pressure climbs back. The disease itself has not been reversed.

At the root is a disease of the vessel wall. Essential hypertension is characterized by endothelial dysfunction — a loss of the endothelium's ability to produce nitric oxide (NO), its primary vasodilator — combined with low-grade systemic inflammation, oxidative stress, and progressive arterial stiffening. These processes create a self-reinforcing cycle: damaged vessels generate more inflammation, more oxidative stress, and more structural remodeling, which raises pressure further and damages the endothelium more deeply.

MSC therapy targets the biology, not just the number. Mesenchymal stem cells are being investigated not as a replacement for antihypertensive drugs, but as a strategy that could address the endothelial, inflammatory, and fibrotic components of the disease that medications leave untouched. The therapeutic potential lies in the MSC secretome — a complex panel of paracrine signals that includes growth factors, anti-inflammatory cytokines, and extracellular vesicles — rather than in any ability of the cells to engraft or differentiate into vascular tissue. [2][3]

Scientific illustration of systemic arteries with endothelial dysfunction and arterial stiffness in hypertension, MSC paracrine signaling targeting the vessel wall
Hypertension is fundamentally a disease of the endothelium and the vessel wall. MSC research targets the vascular biology — the inflammation, oxidative stress, and stiffening — that sphygmomanometer readings alone cannot capture.

What is hypertension and why do existing treatments leave room for improvement

Blood pressure is the force exerted by circulating blood against the walls of the large arteries. It is expressed as two numbers: systolic pressure (the peak pressure during cardiac contraction) and diastolic pressure (the trough pressure between beats). The threshold for hypertension has been progressively lowered as evidence accumulates that even modest elevations — systolic pressures of 130–139 mmHg — carry substantially increased cardiovascular risk. [4]

About 90–95% of hypertension is classified as "essential" or "primary" — meaning no single identifiable cause, but rather a convergence of genetic predisposition, environmental triggers (dietary sodium, sedentary lifestyle, obesity), and the biological processes of aging. The remaining 5–10% is secondary hypertension, attributable to an underlying condition such as renal artery stenosis (renovascular hypertension), chronic kidney disease, primary aldosteronism, or obstructive sleep apnea.

The global burden is staggering. The NCD Risk Factor Collaboration reported that between 1990 and 2019, the number of people aged 30–79 with hypertension doubled from 650 million to 1.28 billion. [5] The prevalence is highest in low- and middle-income countries, where awareness, treatment, and control rates lag farthest behind. Even in high-income nations, only about 50–60% of those treated achieve target blood pressure — a statistic driven as much by biological resistance as by adherence. "Resistant hypertension," defined as blood pressure that remains above goal despite three or more optimally-dosed antihypertensives, affects roughly 10–15% of the treated population.

Key fact

Elevated blood pressure is the leading single risk factor for disease burden worldwide, responsible for an estimated 10.8 million deaths annually. Each 20 mmHg increase in systolic pressure doubles the risk of death from stroke, heart disease, and other vascular causes. Even small, sustained reductions — 5 mmHg lower systolic — produce a 10–15% reduction in major cardiovascular events at the population level. [6]

Why mesenchymal stem cells are being studied for hypertension

The rationale for investigating MSC therapy in hypertension rests on three pillars of the disease that are largely unaddressed by current drugs: endothelial dysfunction, vascular inflammation, and arterial fibrosis. [7]

Endothelial repair. MSCs secrete vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and angiopoietin-1, which promote endothelial cell survival, proliferation, and migration. Preclinical studies have shown that MSC administration restores nitric oxide bioavailability in the endothelium — the critical vasodilatory signal that is lost early in hypertension. In the spontaneously hypertensive rat (SHR), a well-established genetic model, MSC infusion improved endothelium-dependent relaxation and lowered systolic pressure by 20–30 mmHg over several weeks. [8]

Anti-inflammatory and immunomodulatory action. Hypertension is now recognized as a state of low-grade sterile inflammation. The elevated pressure itself damages the vessel wall, triggering immune cell infiltration — particularly T cells and monocytes — which release cytokines that sustain the hypertensive state. MSCs potently suppress this inflammatory cascade by shifting macrophages from the pro-inflammatory M1 phenotype toward the reparative M2 phenotype, by expanding regulatory T cells (Tregs), and by reducing levels of IL-6, TNF-α, and MCP-1. In animal models, these effects translate into measurable reductions in vascular inflammation and blood pressure. [9]

Anti-fibrotic and remodeling effects. Chronic hypertension drives structural remodeling of the arterial wall — the media thickens, collagen accumulates, and the vessel stiffens. This arteriosclerosis increases pulse wave velocity (PWV), elevates systolic pressure disproportionately, and strains the heart. MSC-derived paracrine factors — including prostaglandin E2 (PGE2), TSG-6, and matrix metalloproteinase modulators — inhibit fibroblast activation, reduce collagen deposition, and may attenuate the progression of vascular stiffness. [10]

Renovascular hypertension and the kidney connection. A distinct but overlapping pathway involves the renin-angiotensin-aldosterone system (RAAS). In renovascular hypertension — caused by renal artery stenosis — the ischemic kidney overproduces renin, driving a sustained increase in angiotensin II and aldosterone that raises pressure and damages the contralateral kidney. MSC therapy has been investigated in the 2-kidney 1-clip (2K-1C) model and in swine atherosclerotic renal artery stenosis, where it reduced systolic pressure, improved renal blood flow, decreased sympathetic hyperactivity, and attenuated fibrotic injury in the stenotic kidney. [11][12]

What the preclinical and early clinical evidence shows

The strongest evidence for MSC therapy in hypertension comes from preclinical models. The spontaneously hypertensive rat (SHR) is the most studied model of essential hypertension. Multiple independent groups have reported that intravenous MSC administration produces sustained reductions in systolic pressure — typically 15–30 mmHg — lasting 3–8 weeks after a single infusion. These effects are accompanied by improved endothelial function, reduced vascular oxidative stress, lower aortic wall thickness, and diminished inflammatory markers. [13]

In the 2K-1C model of renovascular hypertension, MSC administration prevents the progressive rise in systolic pressure, reduces renal fibrosis, increases peritubular capillary density, and decreases sympathetic nerve activity driving the hypertensive state. The effect is not merely vasodilatory — it reflects structural repair of the stenotic kidney. MSCs also preserve the ability of the contralateral kidney to excrete sodium, countering the volume-dependent component of renovascular hypertension. [14]

In swine models of atherosclerotic renal artery stenosis — a more translationally relevant platform — intra-arterial infusion of adipose-derived MSCs improved renal blood flow, increased cortical perfusion, reduced tissue inflammation, and attenuated fibrosis. These effects were observed both with cells alone and in conjunction with stent revascularization. [15]

Human data are limited but exist. The landmark clinical study is a Phase 1a escalating-dose trial from Mayo Clinic, in which 21 patients with atherosclerotic renovascular disease (ARVD) received autologous adipose-derived MSCs infused into the renal artery at three dose levels, compared to 18 matched controls receiving medical therapy alone. Three months after infusion, MSC-treated patients showed increased renal blood flow, improved glomerular filtration rate, reduced renal vein inflammatory biomarkers, and — notably — lower blood pressure compared to controls. [16]

These results are encouraging but must be interpreted cautiously. The trial was open-label, non-randomized, and small. The patient population had renovascular hypertension specifically — not the far larger essential hypertension population. And the blood pressure reduction, while measurable, was modest and observed as a secondary endpoint rather than the primary aim of the study. No MSC product has been tested in a randomized controlled trial for essential hypertension.

The honest headline

As of mid-2026, no stem cell product is approved for any form of hypertension. The preclinical evidence is strong and convergent, a single well-conducted Phase 1a trial provides proof-of-concept in renovascular disease, and the safety profile across hundreds of cardiovascular MSC studies is reassuring — but efficacy for essential hypertension has not been established. MSC therapy for high blood pressure remains investigational, and any claim to the contrary overstates the evidence.

How outcomes are measured in hypertension research

Blood pressure is the most direct endpoint, but how it is measured matters. Office blood pressure measurement — the cuff in the clinic — is standard but subject to white-coat effect and observer bias. Ambulatory blood pressure monitoring (ABPM), which records pressure over 24 hours, is more reproducible and better predicts target-organ damage. MSC studies have typically used systolic pressure measured by tail-cuff plethysmography in rodents and by clinic measurement with confirmatory ABPM in human protocols. Endothelial function — assessed by flow-mediated dilation (FMD) of the brachial artery or by reactive hyperemia index — provides a mechanistic window into MSC effects. Arterial stiffness, measured as pulse wave velocity (PWV), reflects the structural remodeling that drives isolated systolic hypertension. Inflammatory biomarkers — IL-6, TNF-α, hsCRP, and MCP-1 — are secondary endpoints that capture the anti-inflammatory action of MSCs. A therapy that alters the course of hypertensive vascular disease should move several of these measures; MSC therapy has shown promising signals in preclinical and early human studies but has not yet cleared the bar of a pivotal trial.

What the evidence supports — and what it does not

A fair appraisal of the current data supports the following: MSC therapy for hypertension appears safe and well tolerated based on the limited human data available. The biological rationale is strong: MSC-derived factors target endothelial repair, inflammation, oxidative stress, and vascular fibrosis — each a core driver of hypertensive pathology. Preclinical efficacy is consistent and convergent: dozens of animal studies report blood pressure reduction together with improvements in endothelial function and vascular structure. A single Phase 1a human trial provides early proof-of-concept for renovascular hypertension specifically. What is missing is efficacy data from randomized placebo-controlled trials in essential hypertension — the disease that affects the overwhelming majority of the 1.28 billion people living with high blood pressure.

Several unknowns remain. The optimal cell source (bone marrow, adipose, umbilical cord), delivery route (intravenous, intra-arterial, intrarenal), dose, and dosing frequency have not been determined. It is unknown how long any blood pressure benefit might persist after a single or repeated MSC infusion — MSCs do not survive long-term in the body, and their paracrine effects are inherently transient. Whether MSC therapy is best positioned as a disease-modifying intervention for early hypertension, an adjunct for resistant hypertension, or a targeted therapy for renovascular hypertension specifically remains unclear. The cost and scalability of clinical-grade MSC manufacturing also present barriers to widespread application even if efficacy is eventually confirmed.

Hypertension is a disease of habit and biology — it takes years of unchecked pressure to reshape the arteries, and years of consistent medication to keep it in check. MSC research asks whether we can interrupt that trajectory at the vessel wall itself, not just manage the pressure it generates. The question is scientifically sound; the answer is not yet in.

— VELAR Clinical Team
Scientific illustration of renal microcirculation showing renovascular hypertension with renal artery narrowing and MSC-mediated anti-inflammatory signaling
Renovascular hypertension — driven by renal artery stenosis and RAAS activation — is one pathway where MSC therapy has shown early clinical proof-of-concept. Whether these findings extend to the much larger population with essential hypertension remains the central unanswered question.

Frequently Asked Questions

Can stem cells cure hypertension?

No. As of 2026, no stem cell therapy has been proven to cure or reverse essential hypertension in humans. MSC therapy is an investigational approach that has shown promise in preclinical models and a single early-phase human trial for renovascular hypertension, but it has not demonstrated disease-modifying efficacy in a randomized controlled trial for the primary hypertensive population. Any claim of a "cure" is not supported by evidence.

How does MSC therapy differ from standard antihypertensive medications?

Standard drugs — ACE inhibitors, ARBs, calcium channel blockers, diuretics, beta-blockers — lower blood pressure by directly altering vascular tone, cardiac output, or fluid balance. They are effective but must be taken daily, often in combination, and they do not reverse the underlying vascular disease. MSC therapy, in theory, targets the endothelial dysfunction, inflammation, and structural remodeling that sustain hypertension — a fundamentally different and potentially complementary mechanism. However, this is a theoretical and preclinical observation, not an established clinical benefit.

What is the cost of stem cell therapy for hypertension in Thailand?

Because MSC therapy for hypertension is investigational and not an approved treatment, pricing structures are not standardized and vary by clinic, cell source, and protocol. At VELAR Center, we do not currently offer MSC therapy specifically for hypertension pending randomized controlled evidence. For approved regenerative indications, costs are discussed during clinical consultation after medical assessment. Be cautious of any provider offering a fixed-price "hypertension stem cell package" — ethical care requires individual assessment, not a menu.

Are there clinical trials for stem cells in hypertension?

Yes, but they are limited. The most notable is the Mayo Clinic Phase 1a trial of autologous MSCs for atherosclerotic renovascular disease (NCT02266394). A small number of additional Phase I studies have been registered or are underway, mostly for renovascular or renal-ischemia indications. No randomized controlled trial has yet been completed for essential hypertension — the form of the disease that accounts for 90–95% of all cases. Larger, blinded Phase II trials in broader hypertensive populations are needed.

How many MSC treatments are needed for hypertension?

There is no established dosing protocol because MSC therapy for hypertension is not an approved treatment. Preclinical studies suggest that a single infusion can lower blood pressure for 3–8 weeks in animal models, and the Phase 1a human study used a single intra-arterial dose. Whether repeated dosing extends the effect, and what the optimal interval might be, remains unknown. Any clinic claiming a specific number of treatments for hypertension is extrapolating beyond the evidence.

Is stem cell therapy safe for people with high blood pressure?

The available safety data are limited but reassuring. In the Phase 1a Mayo Clinic trial, intra-arterial MSC infusion was well tolerated in patients with renovascular disease, including those with impaired kidney function. No serious adverse events attributable to the cell product were reported. Broader safety data from MSC studies in cardiovascular disease — including heart failure and ischemic heart disease — support a favorable safety profile. However, patients with uncontrolled hypertension were typically excluded from these studies, so the safety profile in this specific population is not fully characterized. Intravenous cell infusion carries theoretical risks of microvascular occlusion and should only be administered under medical supervision.

How to evaluate any offer responsibly

If you are considering stem cell options for hypertension, ask these questions. Is the approach part of a registered clinical trial with independent ethical oversight? What specific cell type and source are used? How is blood pressure measured — clinic cuff, home monitoring, or 24-hour ABPM — and are the results published? What peer-reviewed evidence supports the specific protocol being offered? Be skeptical of guaranteed results, percentage-based success claims without a cited source, and any framing that positions an experimental therapy as established treatment. A trustworthy provider will describe MSC therapy for hypertension as emerging research — and will never let enthusiasm outpace the data.

The VELAR perspective

At VELAR Center, we follow hypertension cell-therapy research with genuine interest. The unmet need is vast — 1.28 billion people with hypertension globally, most with suboptimal control — and the preclinical rationale for MSC intervention is among the stronger emerging stories in regenerative cardiovascular medicine. But we also recognize that hypertension is a chronic condition managed effectively by safe, inexpensive drugs for most patients, and that the threshold for adding a cell-based intervention must be high. We do not offer MSC therapy specifically for hypertension at this time, and we believe the only responsible position is to await randomized controlled evidence before doing so. If you want an honest conversation about what is known, what is unknown, and what regenerative medicine can realistically offer today for cardiovascular health, that conversation is always available at VELAR — without obligation, without exaggeration.

References

  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1 ↩
  2. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  3. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Circulation. 2018;138(17):e484-e594. doi:10.1161/CIR.0000000000000596 ↩
  5. NCD-RisC. (see ref-1). doi:10.1016/S0140-6736(21)01330-1 ↩
  6. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA. 2017;317(2):165-182. doi:10.1001/jama.2016.19043 ↩
  7. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Research & Therapy. 2016;7(1):125. doi:10.1186/s13287-016-0363-7 ↩
  8. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  9. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  10. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  11. Oliveira-Sales EB, Maquigussa E, Semedo P, et al. Mesenchymal stem cells and chronic renal artery stenosis. American Journal of Physiology-Renal Physiology. 2016;310(1):F6-F9. doi:10.1152/ajprenal.00341.2015 ↩
  12. Eirin A, Zhu XY, Krier JD, et al. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells. 2012;30(5):1030-1041. doi:10.1002/stem.1263 ↩
  13. Varela VA, Maquigussa E, Ribeiro RS, et al. Treatment with mesenchymal stem cells improves renovascular hypertension and preserves the ability of the contralateral kidney to excrete sodium. Kidney and Blood Pressure Research. 2019;44(6):1404-1415. doi:10.1159/000504595 ↩
  14. Abumoawad A, Saad A, Ferguson CM, et al. In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure. Kidney International. 2020;97(4):793-804. doi:10.1016/j.kint.2019.11.022 ↩
  15. Ebrahimi B, Eirin A, Li Z, et al. Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis. PLoS One. 2013;8(7):e67474. doi:10.1371/journal.pone.0067474 ↩
  16. Wang HS, Hwang IY, Park HS, et al. Effects of mesenchymal stem cells in renovascular disease of preclinical and clinical studies: a systematic review and meta-analysis. Scientific Reports. 2022;12:19852. doi:10.1038/s41598-022-23059-2 ↩
  17. Zhu XY, Urbieta-Caceres V, Krier JD, et al. Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms. Stem Cells. 2013;31(1):117-125. doi:10.1002/stem.1263 ↩
  18. Saad A, Dietz AB, Herrmann SMS, et al. Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease. Journal of the American Society of Nephrology. 2017;28(9):2777-2785. doi:10.1681/ASN.2017020173 ↩
  19. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132-140. doi:10.1161/HYPERTENSIONAHA.110.163576 ↩
  20. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. The Lancet Respiratory Medicine. 2016;4(4):306-322. doi:10.1016/S2213-2600(15)00543-3 ↩